title: Biomarkers for predicting response to regional chemo-immunotherapy in liver metastases from colorectal carcinoma.
abstract: Differences in therapeutic outcomes after regional chemotherapy or chemo-immunotherapy in liver metastases from colorectal carcinoma cannot be explained only by variations in the regimens of treatment. This study was undertaken to assess the potential of several tumor-associated markers of biological behavior (biomarkers) to predict therapeutic response in order to pre-select the best candidates for this demanding treatment. In a group of 21 patients, flow cytometric DNA ploidy provided the most accurate prediction, with a response rate of 88% in 8 DNA diploid tumors compared to 31% in 13 DNA aneuploid cases (P = 0.017) and a difference in overall survival of nine months (20.4 vs 11.3, P = 0.041). Only a slight trend towards improved response rate was observed when we immunohistochemically detected p53 anti-oncoprotein expression in 11 (52%) p53-positive tumors (P = 0.063). Other immunohistochemical biomarkers as P-glycoprotein (p170), p21/WAF, mdm2, c-erbB-2, and proliferative activity of tumor (detected either by anti-PCNA and anti-Ki67 monoclonal antibodies or as a flow cytometric proliferation index) were unrelated to the outcome of treatment. DNA ploidy and expression of p53 protein are potential biomarkers for predicting the response to regional chemotherapy of liver metastases from colorectal carcinoma.
authors.affiliation: Masaryk Memorial Cancer Institute, Brno, Czech Republic.
authors.forename: J
authors.initials: J
authors.lastname: Zaloudik
authors.forename: V
authors.initials: V
authors.lastname: Vagunda
authors.forename: M
authors.initials: M
authors.lastname: Drahokoupilova
authors.forename: L
authors.initials: L
authors.lastname: Janakova
authors.forename: R
authors.initials: R
authors.lastname: Talac
authors.forename: J
authors.initials: J
authors.lastname: Kalabis
authors.forename: M
authors.initials: M
authors.lastname: Sheard
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D014408:Biomarkers, Tumor; D015179:Colorectal Neoplasms; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000235:genetics; D015870:Gene Expression; D005819:Genetic Markers; D006801:Humans; D007167:Immunotherapy; D015552:Injections, Intralesional; D008113:Liver Neoplasms / Q000235:genetics / Q000556:secondary* / Q000628:therapy*; D011003:Ploidies; D011237:Predictive Value of Tests; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D005819:Genetic Markers; D016159:Tumor Suppressor Protein p53